
Tumour minus adjacent predicted log(IC50), all 138 drugs
Welch t 95% CI; drugs ordered by p−value; negative = tumour more sensitive
Roscovitine
AZD6244
PD.0325901
PD.0332991
LFM.A13
JNK.Inhibitor.VIII
WO2009093972
Gefitinib
CCT007093
DMOG
Nutlin.3a
X17.AAG
Bosutinib
Thapsigargin
Metformin
CEP.701
AZD7762
A.443654
Cytarabine
PF.4708671
Erlotinib
AZD.0530
PF.02341066
QS11
JNJ.26854165
AG.014699
BMS.536924
RDEA119
CMK
CI.1040
Rapamycin
Imatinib
AMG.706
BMS.708163
WH.4.023
PF.562271
GW843682X
Doxorubicin
Obatoclax.Mesylate
Sunitinib
SB.216763
A.770041
BIBW2992
Axitinib
Embelin
MK.2206
BIRB.0796
Dasatinib
AUY922
AP.24534
Sorafenib
Bexarotene
AS601245
BX.795
GW.441756
Bicalutamide
FTI.277
BMS.754807
Cyclopamine
Bryostatin.1
Z.LLNle.CHO
Nilotinib
FH535
Gemcitabine
AICAR
GNF.2
IPA.3
AZ628
CGP.082996
VX.702
NSC.87877
CCT018159
Vinorelbine
X681640
MS.275
Vinblastine
Etoposide
Methotrexate
Lenalidomide
AZD8055
JNK.9L
ZM.447439
JW.7.52.1
GSK.650394
SL.0101.1
EHT.1864
CGP.60474
Temsirolimus
ATRA
PLX4720
Pazopanib
CHIR.99021
NVP.TAE684
BAY.61.3606
NU.7441
PD.173074
Cisplatin
GSK269962A
Pyrimethamine
KIN001.135
PAC.1
Lapatinib
Elesclomol
SB590885
Mitomycin.C
ABT.263
AZD6482
OSI.906
XMD8.85
GDC0941
BMS.509744
BI.D1870
Epothilone.B
Shikonin
TW.37
VX.680
MG.132
Bortezomib
Paclitaxel
WZ.1.84
Midostaurin
Camptothecin
Bleomycin
PHA.665752
Parthenolide
KU.55933
GDC.0449
Docetaxel
Tipifarnib
AZD.2281
NVP.BEZ235
BI.2536
ABT.888
AKT.inhibitor.VIII
RO.3306
Salubrinal
Vorinostat
S.Trityl.L.cysteine
−0.5
0.0
0.5
1.0
Difference in predicted log(IC50) (Tumour − Adjacent)
not significant (p>=0.05)
p<0.05, tumour less sensitive
p<0.05, tumour more sensitive